These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34590320)

  • 1. Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components: A review of observed versus modeled infectivity from donors with window period and occult HBV infections.
    Lelie N; Busch M; Kleinman S
    Transfusion; 2021 Nov; 61(11):3190-3201. PubMed ID: 34590320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections.
    Vermeulen M; van Drimmelen H; Coleman C; Mitchel J; Reddy R; Lelie N
    Transfusion; 2014 Oct; 54(10):2496-504. PubMed ID: 24749834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.
    Seed CR; Kiely P
    Vox Sang; 2013 Nov; 105(4):290-8. PubMed ID: 23802710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan.
    Taira R; Satake M; Momose S; Hino S; Suzuki Y; Murokawa H; Uchida S; Tadokoro K
    Transfusion; 2013 Jul; 53(7):1393-404. PubMed ID: 23033944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.
    Tsoi WC; Lelie N; Lin CK
    Transfusion; 2013 Oct; 53(10 Pt 2):2477-88. PubMed ID: 23521050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme.
    Seed CR; Maloney R; Kiely P; Bell B; Keller AJ; Pink J;
    Vox Sang; 2015 Feb; 108(2):113-22. PubMed ID: 25234417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
    González R; Torres P; Castro E; Barbolla L; Candotti D; Koppelman M; Zaaijer HL; Lelie N; Allain JP; Echevarría JM
    Transfusion; 2010 Jan; 50(1):221-30. PubMed ID: 19682332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Different Testing Scenarios in Reducing Transfusion-Transmitted Hepatitis B Virus (TT-HBV) Infection Risk.
    Lelie N; Busch M; Kleinman S
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters.
    Lelie N; Vermeulen M; van Drimmelen H; Coleman C; Bruhn R; Reddy R; Busch M; Kleinman S
    Vox Sang; 2020 Apr; 115(3):133-145. PubMed ID: 31960480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing.
    Lelie N; Bruhn R; Busch M; Vermeulen M; Tsoi WC; Kleinman S;
    Transfusion; 2017 Jan; 57(1):24-35. PubMed ID: 27673757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of occult hepatitis B and window period infection among blood donors by individual donation nucleic acid testing in a tertiary care center in South India.
    Keechilot CS; Shenoy V; Kumar A; Biswas L; Vijayrajratnam S; Dinesh K; Nair P
    Pathog Glob Health; 2016; 110(7-8):287-291. PubMed ID: 27788631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?
    Ekiaby ME; Tanaka J; van Drimmelen H; Allain JP; Lelie N
    J Viral Hepat; 2022 May; 29(5):330-339. PubMed ID: 35274395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of hepatitis B virus infection in German blood donors 2008-2015.
    Scheiblauer H; Heiden M; Funk M; Oberle D; Kreß J; Jork C; Chudy M
    Vox Sang; 2020 Apr; 115(3):152-161. PubMed ID: 32023664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.
    Kiely P; Margaritis AR; Seed CR; Yang H;
    Transfusion; 2014 Aug; 54(8):2084-91. PubMed ID: 24650170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?
    Harvala H; Reynolds C; Gibney Z; Derrick J; Ijaz S; Davison KL; Brailsford S
    Transfusion; 2021 Aug; 61(8):2402-2413. PubMed ID: 34114670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP
    Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen.
    Kuhns MC; Holzmayer V; Anderson M; McNamara AL; Sauleda S; Mbanya D; Duong PT; Dung NTT; Cloherty GA
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.
    Vermeulen M; Dickens C; Lelie N; Walker E; Coleman C; Keyter M; Reddy R; Crookes R; Kramvis A
    Transfusion; 2012 Apr; 52(4):880-92. PubMed ID: 21981386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing.
    van de Laar TJ; Hogema BM; Molenaar-de Backer MW; Marijt-van der Kreek T; Zaaijer HL
    Transfusion; 2021 Jul; 61(7):2116-2124. PubMed ID: 33899233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.